• The medical device company sprouts SaaS-like metrics; 30%+ growth, 80% recurring revenues, 80%+ gross margin and it’s profitable and cash flow positive.
• The big sales force expansion depress these figures now, but will create a tremendous ratcheting up effect later.
• There are multiple expansion opportunities like overseas and other devices.

Source: The Zynex Party Has Much Further To Go – Zynex, Inc. (NASDAQ:ZYXI) | Seeking Alpha